Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 15/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | RAMP1 | O60894 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593027 | 0.83 | CALCRL (0.43) | CALCRLCHRM4RAMP1CYP3A4 | |
| SCHEMBL3601664 | 0.83 | TNKS (0.58) | TNKSCALCRLKDM4EALDH1A1MAPT | |
| SCHEMBL16456393 | 0.81 | TNKS (0.61) | TNKSCALCRLKDM4EALDH1A1MAPT | |
| SCHEMBL2103739 | 0.79 | CALCRL (0.58) | CALCRLCHRM4RAMP1 | |
| SCHEMBL30231301 | 0.79 | CALCRL (0.58) | CALCRLCHRM4RAMP1 | |
| SCHEMBL16456384 | 0.78 | TNKS (0.58) | TNKSCALCRLCHRM4KDM4EALDH1A1 | |
| SCHEMBL13884718 | 0.74 | TNKS (0.46) | TNKSKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4072288 | 0.73 | CALCRL (0.42) | CALCRLCHRM4RAMP1 | |
| SCHEMBL3654157 | 0.73 | USP30 (0.44) | — | |
| Trifluoroacetic Acid SCHEMBL3995834 | 0.73 | TNKS (0.42) | TNKSCALCRLRAMP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| EP-1689493-A4 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-04-23 | — | — | EP | claimed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | claimed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | claimed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-7842808-B2 | calcitonin gene-related peptide receptors antagonists such as 4-(2-Oxo-2,3-dihydro-benzoimidazol-1-yl)-piperidine-1-carboxylic acid[2-(1,4-dioxa-8-aza-spiro [4.5]dec-8-yl)-1-(1H-indol-5-ylmethyl)-2-oxo-ethyl]-amide, used for treating headaches, pain, hot flashes or respiratory system disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-7754732-B2 | Spirocyclic anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-13 | — | — | US | disclosed |
| EP-1689493-A4 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7314883-B2 | Anti-migraine treatments | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-04 | — | — | US | disclosed |
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-7220862-B2 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1689493-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Pharma Company (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005065779-A1 | CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148093-A1 | Non-terminal method of identifying anti-migraine compounds | VDAC1, HTR3B, FAAH | TNKS 986/4885CALCRL 430/4885CHRM4 375/4885 |
| US-20070149503-A1 | ANTI-MIGRAINE SPIROCYCLES | CALCRL, CALCR, CALCA | TNKS 2777/4885CALCRL 1/4885CHRM4 681/4885 |
| US-20070149502-A1 | SPIROCYCLIC ANTI-MIGRAINE COMPOUNDS | CALCRL, CALCR, CALCA | TNKS 2719/4885CALCRL 1/4885CHRM4 637/4885 |
| US-20070232600-A1 | ANTI-MIGRAINE TREATMENTS | BDKRB2, PTGIR, CALCRL | TNKS 2873/4885CALCRL 3/4885CHRM4 280/4885 |
| US-20040204397-A1 | Calcitonin gene related peptide receptor antagonists | CALCRL, CALCA, CALCR | TNKS 3113/4885CALCRL 1/4885CHRM4 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.